XPENG-INC.
21.12.2020 11:48:15 CET | Business Wire | Press release
Xpeng Inc. (“Xpeng” or the “Company”, NYSE: XPEV), a leading Chinese smart electric vehicle company, has started delivery of smart EVs to customers in Norway. 100 Xpeng G3 smart electric SUVs are being handed over to their new owners this week across 28 cities and towns in Norway - the northernmost of which is Bodø (67°N), just north of the Arctic Circle.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201221005331/en/
While the domestic Chinese market remains its primary customer base, Xpeng is now well positioned to develop its international strategy with the launch of its first production model, the G3 electric SUV, in Norway. Xpeng is actively exploring opportunities in other EV-mature markets with supportive government policies, advanced EV infrastructure and high EV awareness as the top priority markets. Xpeng is also planning to launch its second production model, the P7 electric sports sedan, in Europe within the next 12 months.
He Xiaopeng, CEO & Chairman of Xpeng, commented: “This week’s customer deliveries in Norway represent a key milestone in Xpeng’s aspirations to become a truly international smart EV brand. Our launch in Europe comes just as consumers are shifting in increasingly large numbers to more sustainable personal transport, and at a tipping point where governments around the world are stepping up their zero emission efforts. We look forward to being a significant driver in accelerating that transition.”
The highly popular new energy and electric vehicle platform, Fully Charged Show YouTube channel, features the Xpeng G3 in its debut ‘Premiere’ episode. Hosted by renowned EV evangelist, Robert Llewellyn, the show provides an exclusive review of the G3 available in Norway.
The Xpeng G3
Photo & video gallery: Xpeng G3 in Norway
The G3 epitomises Xpeng’s strategy of offering advanced technologies at attractive price points. The list price for the G3 in Norway starts at 358,000 NKr (approx. EUR 33,700 / GBP 30,300 / USD 41,000).
This smart electric SUV is sharply styled, with a panoramic windscreen, and a certified range of 520km NEDC (451km WLTP). The G3 features Xpeng’s proprietary XPILOT 2.5 advanced driver assistance system. The G3’s auto parking function is able to distinguish between parallel and vertical parking spaces, as well as marked and unmarked parking spaces.
The G3 available in Norway features an English language user interface, with the AI-powered “Hi Xpeng” voice assistant, intelligent navigation and remote APP control.
The software for the XPILOT and Xmart OS operating system has been fully developed by Xpeng’s in-house R&D team, a clear example of the company’s approach to smart tech innovation.
Xpeng is uncompromising in its commitment to safety standards, with the G3 boasting a comprehensive suite of safety systems, helping it to achieve a class-best C-NCAP safety rating in China*.
Established in 2015, Xpeng launched its first production model in December 2018, and 2020 year-to-date deliveries of its smart EVs reached 21,341 units by the end of November, representing an 87% increase year-over-year. Xpeng listed on the New York Stock Exchange in August 2020, raising US$1.7 billion with a strong shareholder base including world renowned corporate and institutional investors. The Company completed its first public follow-on offering on 11 December 2020, raising US$2.5 billion.
Media information
About Xpeng Inc.
Xpeng is a leading Chinese smart electric vehicle company that designs, develops, manufactures, and markets Smart EVs that appeal to the large and growing base of technology-savvy middle-class consumers in China. Its mission is to drive Smart EV transformation with technology and data, shaping the mobility experience of the future.
In order to optimize its customers’ mobility experience, Xpeng develops in-house its full-stack autonomous driving technology and in-car intelligent operating system, as well as core vehicle systems including powertrain and the electrification/electronic architecture.
Xpeng is headquartered in Guangzhou, China, with offices in Beijing, Shanghai, Silicon Valley and San Diego. The Company’s Smart EVs are manufactured at plants in Zhaoqing and Zhengzhou, located in Guangdong and Henan provinces, respectively. For more information, please visit https://en.xiaopeng.com/ .
*The Xpeng G3 Smart version completed the C-NCAP safety test in China on 13 July 2019.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201221005331/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bureau Veritas and Trade Technologies Join Forces to Streamline Global Trade Operations30.3.2026 07:45:00 CEST | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), through its Swiss branch Government Services Division, is pleased to announce a strategic agreement with Trade Technologies, the leading provider of trade finance automation, connectivity and transaction management services. This collaboration is a significant step toward reducing the complexities of international trade operations, particularly in regions where regulatory and inspection controls remain stringent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329411683/en/ Addressing Critical Trade Finance Challenges The agreement comes at a pivotal time for global trade. Letters of Credit (LCs) continue to serve as essential instruments in international commerce, particularly across the Middle East and Africa, where counterparty risk, foreign exchange controls, sanctions exposure, and regulatory oversight face ongoing challenges. In
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom